Claim and evidence Close ×
Recursion's prospectus dated 15 April 2021 states an initial public offering of 24,242,424 shares of Class A common stock at $18.00 per share, approved for listing on the Nasdaq Global Select Market under the symbol RXRX. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Provision Statement · provision ID co-recursion-ipo-2021 Date 2021-04-15 · publication Records dated 2021 → Scope and limits The prospectus states the offering terms; it is not evidence of the shares sold after any over-allotment option, the proceeds realised or the closing.
The evidence 02 primary source Supports the claim
Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock ↗ Recursion Pharmaceuticals, Inc. (filed with the US SEC) · 2021-04-15
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “This is the initial public offering of shares of Class A common stock of Recursion Pharmaceuticals, Inc. We are offering 24,242,424 shares of our Class A common stock. The initial public offering price is $18.00 per share.” Location in source Prospectus cover
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Recursion Pharmaceuticals, Inc. (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Recursion Pharmaceuticals, Inc. (filed with the US SEC), “Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock”, 2021-04-15. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (37 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Supports the claim
Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock ↗ Recursion Pharmaceuticals, Inc. (filed with the US SEC) · 2021-04-15
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Paraphrase the cover states that the Class A common stock has been approved for listing on the Nasdaq Global Select Market under the symbol RXRX.
Location in source Prospectus cover
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Recursion Pharmaceuticals, Inc. (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Recursion Pharmaceuticals, Inc. (filed with the US SEC), “Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock”, 2021-04-15. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The paraphrase is Selekoa’s, written from the text retrieved for the candidate pack on 2026-10-30; it is not a quotation and was not machine-matched. Paraphrased because the filing prints the symbol in quotation marks encoded as Windows-1252 character references that the text extraction does not render; the earlier quote marked them with an ellipsis, which misrepresented an omission. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.
Date. Prospectus date; the prospectus states delivery of shares on or about April 20, 2021. Trading and closing dates are not recorded here.
Record ID aib-co-recursion-ipo-2021